Global Checkpoint Inhibitors for Treating Cancer Market Insights, Forecast to 2026
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Checkpoint Inhibitors for Treating Cancer 3900 market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Checkpoint Inhibitors for Treating Cancer 3900 industry.
Based on our recent survey, we have several different scenarios about the Checkpoint Inhibitors for Treating Cancer 3900 YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 7551.9 million in 2019. The market size of Checkpoint Inhibitors for Treating Cancer 3900 will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Checkpoint Inhibitors for Treating Cancer market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Checkpoint Inhibitors for Treating Cancer market in terms of both revenue and volume.
Players, stakeholders, and other participants in the global Checkpoint Inhibitors for Treating Cancer market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on sales (volume), revenue and forecast by each application segment in terms of sales and revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Sales and Pricing Analyses
Readers are provided with deeper sales analysis and pricing analysis for the global Checkpoint Inhibitors for Treating Cancer market. As part of sales analysis, the report offers accurate statistics and figures for sales and revenue by region, by each type segment for the period 2015-2026.
In the pricing analysis section of the report, readers are provided with validated statistics and figures for the price by players and price by region for the period 2015-2020 and price by each type segment for the period 2015-2020.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Checkpoint Inhibitors for Treating Cancer market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of sales for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Checkpoint Inhibitors for Treating Cancer market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Checkpoint Inhibitors for Treating Cancer market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Checkpoint Inhibitors for Treating Cancer market.
The following manufacturers are covered in this report:
Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Checkpoint Inhibitors for Treating Cancer 3900 market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Checkpoint Inhibitors for Treating Cancer 3900 industry.
Based on our recent survey, we have several different scenarios about the Checkpoint Inhibitors for Treating Cancer 3900 YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 7551.9 million in 2019. The market size of Checkpoint Inhibitors for Treating Cancer 3900 will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Checkpoint Inhibitors for Treating Cancer market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Checkpoint Inhibitors for Treating Cancer market in terms of both revenue and volume.
Players, stakeholders, and other participants in the global Checkpoint Inhibitors for Treating Cancer market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on sales (volume), revenue and forecast by each application segment in terms of sales and revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Sales and Pricing Analyses
Readers are provided with deeper sales analysis and pricing analysis for the global Checkpoint Inhibitors for Treating Cancer market. As part of sales analysis, the report offers accurate statistics and figures for sales and revenue by region, by each type segment for the period 2015-2026.
In the pricing analysis section of the report, readers are provided with validated statistics and figures for the price by players and price by region for the period 2015-2020 and price by each type segment for the period 2015-2020.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Checkpoint Inhibitors for Treating Cancer market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of sales for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Checkpoint Inhibitors for Treating Cancer market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Checkpoint Inhibitors for Treating Cancer market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Checkpoint Inhibitors for Treating Cancer market.
The following manufacturers are covered in this report:
- Bristol-Myers Squibb(BMS)
- Merck
- Roche
- ...
- PD-1 Inhibitors
- PD-L1 Inhibitors
- CTLA-4 Inhibitors
- Melanoma Treatment
- Bladder Cancer Treatment
- Other
1 STUDY COVERAGE
1.1 Checkpoint Inhibitors for Treating Cancer Product Introduction
1.2 Market Segments
1.3 Key Checkpoint Inhibitors for Treating Cancer Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type
1.4.2 PD-1 Inhibitors
1.4.3 PD-L1 Inhibitors
1.4.4 CTLA-4 Inhibitors
1.5 Market by Application
1.5.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Application
1.5.2 Melanoma Treatment
1.5.3 Bladder Cancer Treatment
1.5.4 Other
1.6 Coronavirus Disease 2019 (Covid-19): Checkpoint Inhibitors for Treating Cancer Industry Impact
1.6.1 How the Covid-19 is Affecting the Checkpoint Inhibitors for Treating Cancer Industry
1.6.1.1 Checkpoint Inhibitors for Treating Cancer Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Checkpoint Inhibitors for Treating Cancer Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Checkpoint Inhibitors for Treating Cancer Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Estimates and Forecasts
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Revenue 2015-2026
2.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales 2015-2026
2.2 Checkpoint Inhibitors for Treating Cancer Market Size by Region: 2020 Versus 2026
2.2.1 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL CHECKPOINT INHIBITORS FOR TREATING CANCER COMPETITOR LANDSCAPE BY PLAYERS
3.1 Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers
3.1.1 Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2015-2020)
3.1.2 Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturers (2015-2020)
3.2 Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers
3.2.1 Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2015-2020)
3.2.2 Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Checkpoint Inhibitors for Treating Cancer Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Checkpoint Inhibitors for Treating Cancer Revenue in 2019
3.2.5 Global Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Checkpoint Inhibitors for Treating Cancer Price by Manufacturers
3.4 Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Product Types
3.4.1 Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
3.4.3 Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Checkpoint Inhibitors for Treating Cancer Market Size by Type (2015-2020)
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2015-2020)
4.1.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Type (2021-2026)
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2021-2026)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2021-2026)
4.2.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Checkpoint Inhibitors for Treating Cancer Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Checkpoint Inhibitors for Treating Cancer Market Size by Application (2015-2020)
5.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020)
5.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2015-2020)
5.1.3 Checkpoint Inhibitors for Treating Cancer Price by Application (2015-2020)
5.2 Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Application (2021-2026)
5.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2021-2026)
5.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2021-2026)
5.2.3 Global Checkpoint Inhibitors for Treating Cancer Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Checkpoint Inhibitors for Treating Cancer by Country
6.1.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Country
6.1.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Type
6.3 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Application
7 EUROPE
7.1 Europe Checkpoint Inhibitors for Treating Cancer by Country
7.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country
7.1.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Type
7.3 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer by Region
8.1.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region
8.1.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Type
8.3 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Checkpoint Inhibitors for Treating Cancer by Country
9.1.1 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country
9.1.2 Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Type
9.3 Central & South America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer by Country
10.1.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country
10.1.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 UAE
10.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Type
10.3 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Bristol-Myers Squibb(BMS)
11.1.1 Bristol-Myers Squibb(BMS) Corporation Information
11.1.2 Bristol-Myers Squibb(BMS) Description, Business Overview and Total Revenue
11.1.3 Bristol-Myers Squibb(BMS) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
11.1.5 Bristol-Myers Squibb(BMS) Recent Development
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Description, Business Overview and Total Revenue
11.2.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Merck Checkpoint Inhibitors for Treating Cancer Products Offered
11.2.5 Merck Recent Development
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Description, Business Overview and Total Revenue
11.3.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Roche Checkpoint Inhibitors for Treating Cancer Products Offered
11.3.5 Roche Recent Development
11.1 Bristol-Myers Squibb(BMS)
11.1.1 Bristol-Myers Squibb(BMS) Corporation Information
11.1.2 Bristol-Myers Squibb(BMS) Description, Business Overview and Total Revenue
11.1.3 Bristol-Myers Squibb(BMS) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
11.1.5 Bristol-Myers Squibb(BMS) Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Region
12.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Regions 2021-2026
12.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Regions 2021-2026
12.2 North America Checkpoint Inhibitors for Treating Cancer Market Size Forecast (2021-2026)
12.2.1 North America: Checkpoint Inhibitors for Treating Cancer Sales Forecast (2021-2026)
12.2.2 North America: Checkpoint Inhibitors for Treating Cancer Revenue Forecast (2021-2026)
12.2.3 North America: Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2021-2026)
12.3 Europe Checkpoint Inhibitors for Treating Cancer Market Size Forecast (2021-2026)
12.3.1 Europe: Checkpoint Inhibitors for Treating Cancer Sales Forecast (2021-2026)
12.3.2 Europe: Checkpoint Inhibitors for Treating Cancer Revenue Forecast (2021-2026)
12.3.3 Europe: Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Checkpoint Inhibitors for Treating Cancer Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Checkpoint Inhibitors for Treating Cancer Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Region (2021-2026)
12.5 Latin America Checkpoint Inhibitors for Treating Cancer Market Size Forecast (2021-2026)
12.5.1 Latin America: Checkpoint Inhibitors for Treating Cancer Sales Forecast (2021-2026)
12.5.2 Latin America: Checkpoint Inhibitors for Treating Cancer Revenue Forecast (2021-2026)
12.5.3 Latin America: Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Checkpoint Inhibitors for Treating Cancer Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Checkpoint Inhibitors for Treating Cancer Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Checkpoint Inhibitors for Treating Cancer Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Checkpoint Inhibitors for Treating Cancer Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
1.1 Checkpoint Inhibitors for Treating Cancer Product Introduction
1.2 Market Segments
1.3 Key Checkpoint Inhibitors for Treating Cancer Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type
1.4.2 PD-1 Inhibitors
1.4.3 PD-L1 Inhibitors
1.4.4 CTLA-4 Inhibitors
1.5 Market by Application
1.5.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Application
1.5.2 Melanoma Treatment
1.5.3 Bladder Cancer Treatment
1.5.4 Other
1.6 Coronavirus Disease 2019 (Covid-19): Checkpoint Inhibitors for Treating Cancer Industry Impact
1.6.1 How the Covid-19 is Affecting the Checkpoint Inhibitors for Treating Cancer Industry
1.6.1.1 Checkpoint Inhibitors for Treating Cancer Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Checkpoint Inhibitors for Treating Cancer Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Checkpoint Inhibitors for Treating Cancer Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Estimates and Forecasts
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Revenue 2015-2026
2.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales 2015-2026
2.2 Checkpoint Inhibitors for Treating Cancer Market Size by Region: 2020 Versus 2026
2.2.1 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL CHECKPOINT INHIBITORS FOR TREATING CANCER COMPETITOR LANDSCAPE BY PLAYERS
3.1 Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers
3.1.1 Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2015-2020)
3.1.2 Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturers (2015-2020)
3.2 Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers
3.2.1 Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2015-2020)
3.2.2 Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Checkpoint Inhibitors for Treating Cancer Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Checkpoint Inhibitors for Treating Cancer Revenue in 2019
3.2.5 Global Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Checkpoint Inhibitors for Treating Cancer Price by Manufacturers
3.4 Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Product Types
3.4.1 Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
3.4.3 Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Checkpoint Inhibitors for Treating Cancer Market Size by Type (2015-2020)
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2015-2020)
4.1.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Type (2021-2026)
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2021-2026)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2021-2026)
4.2.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Checkpoint Inhibitors for Treating Cancer Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Checkpoint Inhibitors for Treating Cancer Market Size by Application (2015-2020)
5.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020)
5.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2015-2020)
5.1.3 Checkpoint Inhibitors for Treating Cancer Price by Application (2015-2020)
5.2 Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Application (2021-2026)
5.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2021-2026)
5.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2021-2026)
5.2.3 Global Checkpoint Inhibitors for Treating Cancer Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Checkpoint Inhibitors for Treating Cancer by Country
6.1.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Country
6.1.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Type
6.3 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Application
7 EUROPE
7.1 Europe Checkpoint Inhibitors for Treating Cancer by Country
7.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country
7.1.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Type
7.3 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer by Region
8.1.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region
8.1.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Type
8.3 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Checkpoint Inhibitors for Treating Cancer by Country
9.1.1 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country
9.1.2 Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Type
9.3 Central & South America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer by Country
10.1.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country
10.1.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 UAE
10.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Type
10.3 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Bristol-Myers Squibb(BMS)
11.1.1 Bristol-Myers Squibb(BMS) Corporation Information
11.1.2 Bristol-Myers Squibb(BMS) Description, Business Overview and Total Revenue
11.1.3 Bristol-Myers Squibb(BMS) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
11.1.5 Bristol-Myers Squibb(BMS) Recent Development
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Description, Business Overview and Total Revenue
11.2.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Merck Checkpoint Inhibitors for Treating Cancer Products Offered
11.2.5 Merck Recent Development
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Description, Business Overview and Total Revenue
11.3.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Roche Checkpoint Inhibitors for Treating Cancer Products Offered
11.3.5 Roche Recent Development
11.1 Bristol-Myers Squibb(BMS)
11.1.1 Bristol-Myers Squibb(BMS) Corporation Information
11.1.2 Bristol-Myers Squibb(BMS) Description, Business Overview and Total Revenue
11.1.3 Bristol-Myers Squibb(BMS) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
11.1.5 Bristol-Myers Squibb(BMS) Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Region
12.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Regions 2021-2026
12.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Regions 2021-2026
12.2 North America Checkpoint Inhibitors for Treating Cancer Market Size Forecast (2021-2026)
12.2.1 North America: Checkpoint Inhibitors for Treating Cancer Sales Forecast (2021-2026)
12.2.2 North America: Checkpoint Inhibitors for Treating Cancer Revenue Forecast (2021-2026)
12.2.3 North America: Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2021-2026)
12.3 Europe Checkpoint Inhibitors for Treating Cancer Market Size Forecast (2021-2026)
12.3.1 Europe: Checkpoint Inhibitors for Treating Cancer Sales Forecast (2021-2026)
12.3.2 Europe: Checkpoint Inhibitors for Treating Cancer Revenue Forecast (2021-2026)
12.3.3 Europe: Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Checkpoint Inhibitors for Treating Cancer Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Checkpoint Inhibitors for Treating Cancer Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Region (2021-2026)
12.5 Latin America Checkpoint Inhibitors for Treating Cancer Market Size Forecast (2021-2026)
12.5.1 Latin America: Checkpoint Inhibitors for Treating Cancer Sales Forecast (2021-2026)
12.5.2 Latin America: Checkpoint Inhibitors for Treating Cancer Revenue Forecast (2021-2026)
12.5.3 Latin America: Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Checkpoint Inhibitors for Treating Cancer Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Checkpoint Inhibitors for Treating Cancer Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Checkpoint Inhibitors for Treating Cancer Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Checkpoint Inhibitors for Treating Cancer Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
LIST OF TABLES
Table 1. Checkpoint Inhibitors for Treating Cancer Market Segments
Table 2. Ranking of Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type 2020-2026 (g) & (US$ Million)
Table 4. Major Manufacturers of PD-1 Inhibitors
Table 5. Major Manufacturers of PD-L1 Inhibitors
Table 6. Major Manufacturers of CTLA-4 Inhibitors
Table 7. COVID-19 Impact Global Market: (Four Checkpoint Inhibitors for Treating Cancer Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Checkpoint Inhibitors for Treating Cancer Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Checkpoint Inhibitors for Treating Cancer Players to Combat Covid-19 Impact
Table 12. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Application 2020-2026 (g)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Market Size by Region (g) & (US$ Million): 2020 VS 2026
Table 14. Global Checkpoint Inhibitors for Treating Cancer Sales by Regions 2015-2020 (g)
Table 15. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Regions (2015-2020)
Table 16. Global Checkpoint Inhibitors for Treating Cancer Revenue by Regions 2015-2020 (US$ Million)
Table 17. Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2015-2020) (g)
Table 18. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturers (2015-2020)
Table 19. Global Checkpoint Inhibitors for Treating Cancer Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2019)
Table 21. Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Price (2015-2020) (USD/mg)
Table 24. Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
Table 26. Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 29. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2015-2020)
Table 30. Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2015-2020)
Table 32. Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type 2015-2020 (USD/mg)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 34. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2015-2020)
Table 35. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 36. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 37. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 38. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 39. North America Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 40. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 41. North America Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 42. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 43. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 44. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 45. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 46. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 47. Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 48. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 49. Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 50. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 51. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2015-2020) (g)
Table 52. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2015-2020)
Table 53. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2015-2020) (US$ Million)
Table 54. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2015-2020)
Table 55. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 56. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 57. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 58. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 59. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 60. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 61. Latin Americaa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 62. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 63. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 64. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 65. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 66. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 67. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 68. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 69. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 70. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 72. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 73. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 74. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 75. Bristol-Myers Squibb(BMS) Corporation Information
Table 76. Bristol-Myers Squibb(BMS) Description and Major Businesses
Table 77. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Production (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2015-2020)
Table 78. Bristol-Myers Squibb(BMS) Product
Table 79. Bristol-Myers Squibb(BMS) Recent Development
Table 80. Merck Corporation Information
Table 81. Merck Description and Major Businesses
Table 82. Merck Checkpoint Inhibitors for Treating Cancer Production (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2015-2020)
Table 83. Merck Product
Table 84. Merck Recent Development
Table 85. Roche Corporation Information
Table 86. Roche Description and Major Businesses
Table 87. Roche Checkpoint Inhibitors for Treating Cancer Production (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2015-2020)
Table 88. Roche Product
Table 89. Roche Recent Development
Table 90. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Regions (2021-2026) (g)
Table 91. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Regions (2021-2026)
Table 92. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 93. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Regions (2021-2026)
Table 94. North America: Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) (g)
Table 95. North America: Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) (US$ Million)
Table 96. Europe: Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) (g)
Table 97. Europe: Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) (US$ Million)
Table 98. Asia Pacific: Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2021-2026) (g)
Table 99. Asia Pacific: Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2021-2026) (US$ Million)
Table 100. Latin America: Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) (g)
Table 101. Latin America: Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) (US$ Million)
Table 102. Middle East and Africa: Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) (g)
Table 103. Middle East and Africa: Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) (US$ Million)
Table 104. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 105. Key Challenges
Table 106. Market Risks
Table 107. Main Points Interviewed from Key Checkpoint Inhibitors for Treating Cancer Players
Table 108. Checkpoint Inhibitors for Treating Cancer Customers List
Table 109. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
Table 1. Checkpoint Inhibitors for Treating Cancer Market Segments
Table 2. Ranking of Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type 2020-2026 (g) & (US$ Million)
Table 4. Major Manufacturers of PD-1 Inhibitors
Table 5. Major Manufacturers of PD-L1 Inhibitors
Table 6. Major Manufacturers of CTLA-4 Inhibitors
Table 7. COVID-19 Impact Global Market: (Four Checkpoint Inhibitors for Treating Cancer Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Checkpoint Inhibitors for Treating Cancer Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Checkpoint Inhibitors for Treating Cancer Players to Combat Covid-19 Impact
Table 12. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Application 2020-2026 (g)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Market Size by Region (g) & (US$ Million): 2020 VS 2026
Table 14. Global Checkpoint Inhibitors for Treating Cancer Sales by Regions 2015-2020 (g)
Table 15. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Regions (2015-2020)
Table 16. Global Checkpoint Inhibitors for Treating Cancer Revenue by Regions 2015-2020 (US$ Million)
Table 17. Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2015-2020) (g)
Table 18. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturers (2015-2020)
Table 19. Global Checkpoint Inhibitors for Treating Cancer Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2019)
Table 21. Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Price (2015-2020) (USD/mg)
Table 24. Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
Table 26. Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 29. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2015-2020)
Table 30. Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2015-2020)
Table 32. Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type 2015-2020 (USD/mg)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 34. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2015-2020)
Table 35. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 36. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 37. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 38. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 39. North America Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 40. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 41. North America Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 42. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 43. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 44. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 45. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 46. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 47. Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 48. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 49. Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 50. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 51. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2015-2020) (g)
Table 52. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2015-2020)
Table 53. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2015-2020) (US$ Million)
Table 54. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2015-2020)
Table 55. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 56. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 57. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 58. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 59. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 60. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 61. Latin Americaa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 62. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 63. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 64. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 65. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 66. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 67. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 68. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 69. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 70. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 72. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Table 73. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 74. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 75. Bristol-Myers Squibb(BMS) Corporation Information
Table 76. Bristol-Myers Squibb(BMS) Description and Major Businesses
Table 77. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Production (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2015-2020)
Table 78. Bristol-Myers Squibb(BMS) Product
Table 79. Bristol-Myers Squibb(BMS) Recent Development
Table 80. Merck Corporation Information
Table 81. Merck Description and Major Businesses
Table 82. Merck Checkpoint Inhibitors for Treating Cancer Production (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2015-2020)
Table 83. Merck Product
Table 84. Merck Recent Development
Table 85. Roche Corporation Information
Table 86. Roche Description and Major Businesses
Table 87. Roche Checkpoint Inhibitors for Treating Cancer Production (g), Revenue (US$ Million), Price (USD/mg) and Gross Margin (2015-2020)
Table 88. Roche Product
Table 89. Roche Recent Development
Table 90. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Regions (2021-2026) (g)
Table 91. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Regions (2021-2026)
Table 92. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 93. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Regions (2021-2026)
Table 94. North America: Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) (g)
Table 95. North America: Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) (US$ Million)
Table 96. Europe: Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) (g)
Table 97. Europe: Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) (US$ Million)
Table 98. Asia Pacific: Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2021-2026) (g)
Table 99. Asia Pacific: Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2021-2026) (US$ Million)
Table 100. Latin America: Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) (g)
Table 101. Latin America: Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) (US$ Million)
Table 102. Middle East and Africa: Checkpoint Inhibitors for Treating Cancer Sales Forecast by Country (2021-2026) (g)
Table 103. Middle East and Africa: Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Country (2021-2026) (US$ Million)
Table 104. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 105. Key Challenges
Table 106. Market Risks
Table 107. Main Points Interviewed from Key Checkpoint Inhibitors for Treating Cancer Players
Table 108. Checkpoint Inhibitors for Treating Cancer Customers List
Table 109. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Checkpoint Inhibitors for Treating Cancer Product Picture
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2020 & 2026
Figure 3. PD-1 Inhibitors Product Picture
Figure 4. PD-L1 Inhibitors Product Picture
Figure 5. CTLA-4 Inhibitors Product Picture
Figure 6. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2020 & 2026
Figure 7. Melanoma Treatment
Figure 8. Bladder Cancer Treatment
Figure 9. Other
Figure 10. Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure 11. Global Checkpoint Inhibitors for Treating Cancer Market Size 2015-2026 (US$ Million)
Figure 12. Global Checkpoint Inhibitors for Treating Cancer Sales 2015-2026 (g)
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2015-2020)
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2019
Figure 16. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2015-2020)
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2019
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Checkpoint Inhibitors for Treating Cancer Revenue in 2019
Figure 20. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Figure 22. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2019
Figure 23. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2015-2020)
Figure 24. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type in 2019
Figure 25. Global Checkpoint Inhibitors for Treating Cancer Market Share by Price Range (2015-2020)
Figure 26. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Figure 27. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2019
Figure 28. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2015-2020)
Figure 29. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application in 2019
Figure 30. North America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2015-2020 (g)
Figure 31. North America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 33. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 34. U.S. Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 35. U.S. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 37. Canada Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2019
Figure 39. North America Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2019
Figure 40. Europe Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2015-2020 (g)
Figure 41. Europe Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 43. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 44. Germany Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 45. Germany Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 47. France Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 49. U.K. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 51. Italy Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 53. Russia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2019
Figure 55. Europe Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2019
Figure 56. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2015-2020 (g)
Figure 57. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2019
Figure 59. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2019
Figure 60. China Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 61. China Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 63. Japan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 65. South Korea Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 67. India Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 69. Australia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 71. Taiwan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 73. Indonesia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 75. Thailand Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 77. Malaysia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 79. Philippines Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 81. Vietnam Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2019
Figure 83. Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2019
Figure 84. Latin America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2015-2020 (g)
Figure 85. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 87. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 88. Mexico Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 89. Mexico Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 91. Brazil Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 93. Argentina Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2019
Figure 95. Latin America Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2019
Figure 96. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2015-2020 (g)
Figure 97. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 100. Turkey Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 101. Turkey Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 103. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. UAE Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 105. UAE Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2019
Figure 107. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2019
Figure 108. Bristol-Myers Squibb(BMS) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 109. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. North America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Forecast (2021-2026) (g)
Figure 112. North America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Forecast (2021-2026) (g)
Figure 114. Europe Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Forecast (2021-2026) (g)
Figure 116. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Forecast (2021-2026) (g)
Figure 118. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Forecast (2021-2026) (g)
Figure 120. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
Figure 1. Checkpoint Inhibitors for Treating Cancer Product Picture
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2020 & 2026
Figure 3. PD-1 Inhibitors Product Picture
Figure 4. PD-L1 Inhibitors Product Picture
Figure 5. CTLA-4 Inhibitors Product Picture
Figure 6. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2020 & 2026
Figure 7. Melanoma Treatment
Figure 8. Bladder Cancer Treatment
Figure 9. Other
Figure 10. Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure 11. Global Checkpoint Inhibitors for Treating Cancer Market Size 2015-2026 (US$ Million)
Figure 12. Global Checkpoint Inhibitors for Treating Cancer Sales 2015-2026 (g)
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2015-2020)
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2019
Figure 16. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2015-2020)
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2019
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Checkpoint Inhibitors for Treating Cancer Revenue in 2019
Figure 20. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
Figure 22. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2019
Figure 23. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2015-2020)
Figure 24. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type in 2019
Figure 25. Global Checkpoint Inhibitors for Treating Cancer Market Share by Price Range (2015-2020)
Figure 26. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Figure 27. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2019
Figure 28. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2015-2020)
Figure 29. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application in 2019
Figure 30. North America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2015-2020 (g)
Figure 31. North America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 33. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 34. U.S. Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 35. U.S. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 37. Canada Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2019
Figure 39. North America Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2019
Figure 40. Europe Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2015-2020 (g)
Figure 41. Europe Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 43. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 44. Germany Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 45. Germany Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 47. France Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 49. U.K. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 51. Italy Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 53. Russia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2019
Figure 55. Europe Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2019
Figure 56. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2015-2020 (g)
Figure 57. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2019
Figure 59. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2019
Figure 60. China Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 61. China Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 63. Japan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 65. South Korea Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 67. India Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 69. Australia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 71. Taiwan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 73. Indonesia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 75. Thailand Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 77. Malaysia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 79. Philippines Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 81. Vietnam Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2019
Figure 83. Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2019
Figure 84. Latin America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2015-2020 (g)
Figure 85. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 87. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 88. Mexico Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 89. Mexico Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 91. Brazil Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 93. Argentina Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2019
Figure 95. Latin America Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2019
Figure 96. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2015-2020 (g)
Figure 97. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 100. Turkey Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 101. Turkey Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 103. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. UAE Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 105. UAE Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2019
Figure 107. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2019
Figure 108. Bristol-Myers Squibb(BMS) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 109. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. North America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Forecast (2021-2026) (g)
Figure 112. North America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Forecast (2021-2026) (g)
Figure 114. Europe Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Forecast (2021-2026) (g)
Figure 116. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Forecast (2021-2026) (g)
Figure 118. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Forecast (2021-2026) (g)
Figure 120. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
